9/11 Study Shows How Toxic Exposures May Lead to Blood Cancers

BRONX, N.Y., Oct. 1, 2025 /PRNewswire/ -- A study led by researchers at the National Cancer Institute-designated Montefiore Einstein Comprehensive Cancer Center (MECCC) has found that mutations in blood-forming cells may explain the increased risk for leukemia and other blood disorders among first responders exposed to the 9/11 World Trade Center (WTC) disaster site and its toxic dust. The study also points to a novel strategy for use against inflammation and blood disorders associated with environmental toxins. The research was published today in Cancer Discovery, a journal of the American Association for Cancer Research.

"Our findings provide new insights into the long-term health impacts of environmental catastrophes, such as wildfires, and suggest targeted interventions for those affected by 9/11 or similar disasters," said study leader Amit Verma, M.D., associate director for translational science, MECCC; chair of oncology at Albert Einstein College of Medicine and Montefiore Health System; and professor of oncology, of medicine, and of developmental & molecular biology at Einstein.

The collapse of the WTC produced tremendous quantities of airborne particulate matter—a potent mixture of carcinogens and genetically toxic substances to which an estimated 400,000 responders, area workers, and residents were exposed. In previous studies, Montefiore Einstein researchers noted a higher incidence of cancers, cardiovascular disease, and other health problems among 9/11 first responders compared with the general population. However, few studies have examined how such environmental exposures can lead to blood cancers.

Toxic Dust and Unique Genetic Changes
For this study, Einstein scientists sequenced blood samples from nearly 1,000 first responders who were exposed to the WTC site, along with blood from two control groups: 255 firefighters who were not at the WTC and 198 unexposed people in the general population. All samples were collected between December 2013 and October 2015. The toxic 9/11 dust cloud was found to be associated with mutations in the blood cells of many responders.

Compared with control-group individuals, WTC-exposed first responders had a significantly higher prevalence of clonal hematopoiesis (CH)—a condition in which a group, or clone, of a person's blood-forming (hematopoietic) stem cells contain the same gene mutations. Typically associated with aging, CH is a pre-cancerous condition known to increase the risk of blood cancer and inflammation.

Overall, first responders with elevated CH mutations were nearly six times likelier to develop leukemia than those without the mutations. Exposure of mice to WTC dust led to high levels of inflammatory markers and an increase in mutant cells, suggesting that toxin-induced inflammation plays a key role in propagating the blood cells.

In addition, researchers found that younger first responders (those under age 60) with elevated CH possessed a set of gene mutations quite distinct from the classic mutations associated with age-related CH—indicating that the gene-altering toxins in WTC dust may contribute to cancer risk by accelerating the aging process.

Identifying a Protein Culprit 
To learn how exposure to toxins is associated with CH mutations and increased leukemia risk, the researchers tested the dust collected from the WTC site in a mouse model. The dust caused an inflammatory response traced to the protein IL1RAP; the high levels of IL1RAP were associated with increased numbers of defective blood-forming stem cells—mimicking the high CH levels observed in the first responders. Importantly, the researchers found they could prevent the rise in defective mutant cells by knocking out the gene that codes for IL1RAP. 

"We now know that IL1RAP is a very attractive target for strategies aimed at suppressing the growth of these mutant clones," said Dr. Verma, who is also the Susan Resnick Fisher Academic Chair in Brain Cancer Research at Einstein. He noted that IL1RAP has been implicated in many types of cancer as well in inflammatory and autoimmune diseases and that several drugs aimed at inhibiting the protein are being evaluated in clinical trials.

"Our work has implications for people exposed to wildfires, air pollution, military burn pits, and many other exposures," said Dr. Verma. "By screening toxin-exposed populations for CH, we could identify people at risk for blood cancers and then potentially treat or even prevent those cancers by targeting IL1RAP."

The study is titled, "Elevated clonal hematopoiesis in environmentally exposed 9/11 first responders has distinct age-related patterns and relies on IL1RAP for clonal expansion." The co-corresponding authors are Divij Verma, Ph.D., Ulrich Steidl, M.D., Ph.D., both at Einstein; David Prezant, M.D., at Einstein and the Fire Department of the City of New York; and Michael Savona, M.D., at Vanderbilt-Ingram Cancer Center, Nashville, TN. Rachel Zeig-Owens, Dr.P.H., and David Goldfarb, M.D., are co-first authors with Dr. D. Verma at Einstein. The work was in part supported by the Jane and Myles Dempsey Fund, the Neil Hirsch Foundation, the Edward John and Patricia Rosenwald Foundation, Blood Cancer United (formerly Leukemia & Lymphoma Society), the Edward P. Evans MDS Foundation and the Valvano Foundation.

About Albert Einstein College of Medicine
Albert Einstein College of Medicine is one of the nation's premier centers for research, medical education and clinical investigation. During the 2024-25 academic year, Einstein is home to 712 M.D. students, 226 Ph.D. students, 112 students in the combined M.D./Ph.D. program, and approximately 250 postdoctoral research fellows. The College of Medicine has more than 2,000 full-time faculty members located on the main campus and at its clinical affiliates. In 2024, Einstein received more than $192 million in awards from the National Institutes of Health. This includes the funding of major research centers at Einstein in cancer, aging, intellectual development disorders, diabetes, clinical and translational research, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Its partnership with Montefiore, the University Hospital and academic medical center for Einstein, advances clinical and translational research to accelerate the pace at which new discoveries become the treatments and therapies that benefit patients. For more information, please visit einsteinmed.edu, follow us on Twitter, Facebook, Instagram, LinkedIn, and view us on YouTube. 

SOURCE Montefiore Einstein Comprehensive Cancer Center